Aletho News

ΑΛΗΘΩΣ

Vitamin D, First clinical trial

Dr. John Campbell | September 6, 2020

About 42% of the US population is vitamin D deficient

82% in black people

70% in Hispanics

Association of Vitamin D Status and Other Clinical Characteristics With COVID-19 Test Results, (JAMA Open, 3rd September, Chicago)

https://jamanetwork.com/journals/jama…

Cohort study of 489 Patients who had a vitamin D level measured in the year before COVID-19 testing

Relative risk of testing positive for COVID-19 was 1.77 times

First clinical trial on vitamin D and COVID Therapy versus best Available Therapy on Intensive Care Unit Admission and Mortality Among Patients Hospitalized for COVID-19: A Pilot Randomized Clinical study (Spain, Journal of steroid biochemistry and molecular biology)

https://www.sciencedirect.com/science…

Objective

Vitamin D decreases Acute Respiratory Distress Syndrome

Effect of calcifediol treatment

Calcifediol can rapidly increase serum 25OHD concentration

25-hydroxyvitamin D

Intensive Care Unit Admission and Mortality

Spanish patients hospitalized for COVID-19.

Design

Parallel pilot, randomized, double-masked clinical trial

Setting

Reina Sofia University Hospital, Córdoba, Spain

Participants

76 consecutive patients hospitalized with COVID-19 infection

Clinical picture of acute respiratory infection

Confirmed by a radiographic pattern of viral pneumonia

Positive SARS-CoV-2 PCR

Procedures

All hospitalized patients received as best available therapy

Hydroxychloroquine and azithromycin

Allocated at a 2 calcifediol:1

Oral calcifediol (0.532 mg), or not

Oral calcifediol (0.266 mg) on day 3 and 7

Then weekly until discharge

End points, ICU admission and deaths.

Results

50 patients treated with calcifediol

One required admission to the ICU (2%),

Of 26 untreated patients, 13 required admission (50%)

p  less than 0.001

Of the patients treated with calcifediol, none died, and all were discharged, without complications

Of the patients not treated, 2 died

Conclusion

Calcifediol seems to be able to reduce severity of the disease

Larger trials with groups properly matched will be required to show a definitive answer

Rationale, activation of the vitamin D receptor (VDR) signalling pathway

Reduced ARDS

Cytokine/chemokine storm

Regulating the renin angiotensin system

Modulating neutrophil activity

Maintaining the integrity of the pulmonary epithelial barrier

Stimulating epithelial repair

Tapering down the increased coagulability

September 10, 2020 - Posted by | Economics, Science and Pseudo-Science, Timeless or most popular, Video |

No comments yet.

Leave a comment

« Previous | Next »